At a Glance
- Study Type: Clinical Trial
- Condition: Fragile X Syndrome
- Age: 6–25
- Sex: All
- Participant: Has FXS plus parent or caregiver
- Location: MIND Institute, Sacramento, CA
- Travel Considerations: At research facility, travel reimbursement available
We are actively recruiting individuals diagnosed with FXS ages 6–25 to participate!
We have preliminary evidence that metformin, a common type 2 diabetes medication, is beneficial for language, cognition, and behavior in both children and adults with Fragile X Syndrome. It is our hope that this study will lead to a better understanding of the benefits of treatment with metformin for individuals with FXS and inform future treatment and interventions.
Q: Who can participate?
- Individuals 6–25 years of age diagnosed with FXS.
- A reliable parent or caregiver who can report the side effects and communicate effectively with the research team for 4 months.
- Study excludes individuals who have taken metformin in the past year.
- Study excludes individuals with other serious illness or medical problem that would interfere with the study.
Q: What does the study involve?
- Three visits to the MIND Institute (located in Sacramento, California).
- Travel reimbursement available per research facility visit.
- Subjects will participate in cognitive, language, sensory, and social assessments administered by the MIND Institute team.
- Caregivers/parents will complete behavioral questionnaires.
- Medical appointments with Dr. Randi Hagerman and her team.
- Randomized assignment to either metformin or placebo capsules, with routine follow-up by research team.
- Three blood draws.
Q: What else is expected?
- Subjects may experience an improvement in physical health, behavioral symptoms, and/or cognitive abilities as a result of treatment with metformin.
- Families can receive feedback on the subject’s performance on the standardized tests that are part of the study.
- Results from this study will have the potential to positively influence the trajectory of development in FXS.
About the MIND Institute
The UC Davis MIND Institute is a collaborative international research center, committee to the awareness, understanding, prevention, and care of neurodevelopmental disorders. Visit mindinstitute.ucdavis.edu for more information.
All studies take place at: MIND Institute, 2825 50th Street, Sacramento, California, 95817
“We can’t have real targeted treatments for Fragile X syndrome that will improve lives more than current supportive treatments without doing science that’s totally new and going where no clinician, researcher, or the FDA has gone before.”
View More Opportunities
The UC Davis MIND Institute is currently recruiting study research participants. The study’s goal is to better understand the ways in which characteristics of mothers and fathers and relationships within the family influence the language learning environment of young boys with Fragile X syndrome.
This survey will help support families in the Early Check study in NC whose newborns have been diagnosed with Fragile X and inform the design of an early intervention program for these babies.
RTI Int’l and UNC at Chapel Hill are conducting a research study to learn more about early development of young children with Fragile X in North Carolina, and the experiences of their parents when obtaining the diagnosis and early intervention services.
A survey to measure levels of behavior. When someone with FXS is experiencing anxiety, describe what you see and hear, and how the experience impacts your/their quality of life.